Gepotidacin (GSK2140944) In Vitro Activity against Gram-Positive and Gram-Negative Bacteria.

about

In Vitro Activities of Gepotidacin (GSK2140944) and Other Antimicrobial Agents Against Human Mycoplasmas and Ureaplasmas.Cellular pharmacokinetics and intracellular activity of gepotidacin against Staphylococcus aureus with different resistance phenotypes in models of cultured phagocytic cells.

P2860

Q40103287-794DFC94-0B79-4BB6-8200-0FCC7F5A21F1 Q49874631-FA0A37E4-B683-45D2-BAD6-4EC9D6AD3D02

P2860

Gepotidacin (GSK2140944) In Vitro Activity against Gram-Positive and Gram-Negative Bacteria.

Item

http://www.wikidata.org/entity/Q38797016

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Gepotidacin (GSK2140944) In Vi ...... ve and Gram-Negative Bacteria.

@en

type

Item

label

Gepotidacin (GSK2140944) In Vi ...... ve and Gram-Negative Bacteria.

@en

prefLabel

Gepotidacin (GSK2140944) In Vi ...... ve and Gram-Negative Bacteria.

@en

P1476

Gepotidacin (GSK2140944) In Vi ...... ve and Gram-Negative Bacteria.

@en

P2093

D J Farrell

http://www.w3.org/2001/XMLSchema#string

H S Sader

http://www.w3.org/2001/XMLSchema#string

N E Scangarella-Oman

http://www.w3.org/2001/XMLSchema#string

P R Rhomberg

http://www.w3.org/2001/XMLSchema#string

R K Flamm

http://www.w3.org/2001/XMLSchema#string

P2860

Type IIA topoisomerase inhibition by a new class of antibacterial agents

Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci

NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy.

In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens.

Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin

Multicenter Investigation of Gepotidacin (GSK2140944) Agar Dilution Quality Control Determinations for Neisseria gonorrhoeae ATCC 49226.

Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of Staphylococcus aureus.

Target-based resistance in Pseudomonas aeruginosa and Escherichia coli to NBTI 5463, a novel bacterial type II topoisomerase inhibitor.

Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem.

P31

scholarly article

P356

10.1128/AAC.00468-17

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28483959

http://www.w3.org/2001/XMLSchema#string

P921

Gram-negative bacteria

Gram-positive bacteria

P932

5487655

http://www.w3.org/2001/XMLSchema#string

Gepotidacin (GSK2140944) In Vitro Activity against Gram-Positive and Gram-Negative Bacteria.

about

P2860

P2860

Gepotidacin (GSK2140944) In Vitro Activity against Gram-Positive and Gram-Negative Bacteria.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P433

P478

P577

P698

P921

P932